Checking your infectious-disease risk should be as simple as checking the weather. That is the idea an Austin startup is trying to make real.
Resilienci.ai is a digital health company that combines public-health guidance, artificial intelligence and large data sets to help ordinary people - and the agencies that serve them - understand local infectious-disease risk in real time. Founded in Austin, Texas by Eric Klasson and operating under the banner "A Pandemic Insights Company," it sets an unusually broad goal: to build the world's first interoperable, multi-pathogen digital health consumer solution for outbreaks and pandemics.
The company's premise is that most outbreak data is nearly useless to a person making a decision. Numbers reported by country, state or even city do not tell you whether it is safe to visit a relative, attend an event, or send a child to school. Resilienci.ai argues that for data to be actionable it has to be hyperlocal and daily - "not just by country, state or city, but down to a building address" - and delivered in real time.
To close that gap, the company pairs a free consumer mobile app with a web-based platform for public health agencies. Individuals get personal and building-level risk indexes, prevention strategies and treatment options. Agencies get a decision tool for national and local counter-measures. The stated aim on both sides is the same: reduce the duration, infection rate and death toll of outbreaks.
Resilienci.ai began, like much of the category, with COVID-19. It has since widened its scope - expanding toward monitoring all known pathogens and directing a comprehensive consumer solution at the Mpox outbreak in Africa. The through-line is a belief that pathogen surveillance is not an emergency response but an ongoing, permanent need.
People deciding whether to commute, travel, shop, dine or gather get personal and building-level risk indexes and prevention guidance - free, and designed so protection is not based on ability to pay.
Employers and regulated industries use Resilience Indexes to manage workforce safety, on-site/remote/hybrid strategies and continuity planning - so preparedness is already deployed if and when it is needed.
Agencies and governments get a web-based platform to weigh national and local counter-measures, with the goal of shortening and softening the impact of outbreaks.
An AI-built Infectious Disease Response and Prevention Platform that reimagines pathogen surveillance for consumers and public health agencies worldwide, pairing a consumer app with agency-facing tools for real-time, hyperlocal risk and actionable insight.
Helps users navigate any outbreak through personal and building risk indexes, prevention strategies and treatment options - offered at no cost, with data anonymized and protected by the company's pandemic-privacy patent.
A web-based platform that lets public-health experts and policy advisors make informed decisions about national and local counter-measures to reduce the duration and impact of outbreaks.
The company's original "smart movement" suite: Roamwell Mobile for consumers and Roamwell Business, a SaaS instance for enterprises and governments using Resilience Indexes to manage workforce safety and continuity.
Most infectious-disease tools are built for epidemiologists and health ministries. Resilienci.ai's most distinctive choice is to point the same intelligence at an individual person - the grandmother, the commuter, the traveler - and make the consumer app free. Adoption, the company argues, follows what users choose, and information that saves lives should not carry a price tag.
The second difference is granularity. Rather than dashboards that stop at the city line, Resilienci.ai emphasizes daily, address-level risk. The third is breadth: an explicitly interoperable, multi-pathogen design intended to move from COVID-19 to Mpox to, eventually, all known pathogens on one platform.
The fourth is privacy. In a category where data usefulness and personal privacy are usually framed as a tradeoff, Resilienci.ai says user data is fully anonymized and protected by a pandemic-privacy patent - a stance codified in its PACT values below.
Compared with digital-epidemiology peers - firms such as BlueDot, Metabiota, HealthMap and consumer-signal players like Kinsa - the combination of free, consumer-first, hyperlocal, multi-pathogen and privacy-anonymized is the position Resilienci.ai stakes out as its own.
A vigorous defense of personal privacy is treated as necessary to success.
Information that saves lives should be free and available to everyone.
Users adopt what users choose - decisions stay with the individual.
Trust comes naturally to those with nothing to hide.
Resilienci.ai runs a two-sided model. The consumer mobile app (B2C/D2C) is free, supported by public-private partnership and philanthropy. The other side is a paid SaaS platform (B2B/B2G) sold to enterprises, regulated industries and public health agencies for surveillance, workforce-resilience and outbreak-response insight. It is a quiet answer to healthtech's oldest question: who pays when the mission is that everyone deserves access?
The company positions itself inside the broader field of digital epidemiology and outbreak analytics - a space that swelled during COVID-19 and has been searching for durable footing since. Resilienci.ai's bet is that the calm between pandemics is exactly when preparedness infrastructure should be built, not abandoned.
Its founding roster reflects how hard the problem is: a cross-disciplinary board spanning artificial intelligence, public health, law, medicine and finance. That breadth is a feature - building an interoperable, privacy-protected, government-grade health tool is as much a legal and policy challenge as a technical one.
Where it fits: a consumer-facing entry point into a market historically dominated by institutional dashboards and government surveillance systems - trying to make outbreak awareness a mainstream, everyday habit rather than a specialist's tool.
Founder and CEO Eric Klasson is a longtime entrepreneur and C-level executive with a four-decade career spanning Price Waterhouse, PepsiCo and ConAgra, followed by a decade focused on AI and machine-learning ventures. He holds an economics degree from the University of Michigan and an MBA from Texas A&M, and has spent three decades on food-insecurity and non-profit boards. Around him sits a board of directors drawn from law, medicine, finance and public affairs.
Co-developing digital health solutions for individuals, families and public health agencies to manage outbreaks, from preparedness to response.
Place/location-data collaboration; Resilienci.ai was featured in a Foursquare case study and appeared at REImagine TEDx Water Street.
Public-private collaboration to deliver interoperable digital health tools and agency-facing surveillance solutions.
Cited engagement with institutions such as the World Economic Forum, WHO and Africa CDC to bring a free interoperable app to market.
Eric Klasson launches Resilienci.ai as a Pandemic Insights venture responding to COVID-19.
The company raises a Series A round in March 2021 to build its resilience and digital health platform.
Roamwell Mobile and Roamwell Business bring Resilience Indexes to consumers and enterprises.
Resilienci.ai discusses pandemic human resiliency at REImagine TEDx Water Street and in a Foursquare case study.
The company reframes around Rapid-AI infectious-disease surveillance and targets outbreaks like Mpox in Africa.
It uses AI, machine learning and hyperlocal data to help people and public health agencies understand and reduce infectious-disease risk through a free consumer app and an agency-facing platform.
It was founded by Eric Klasson (Founder & CEO) and is headquartered in Austin, Texas.
Yes. The consumer mobile app is offered at no cost, based on the company's belief that life-saving health information should be available to everyone regardless of ability to pay.
It emphasizes real-time, hyperlocal risk down to a building address, a consumer-first design, multi-pathogen coverage, and anonymized, privacy-protected data.
It raised a $5 million Series A round in March 2021.